Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fitscha

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
American Journal of Hypertension|February 1, 1991
Effects of isradipine on platelet function in hypertension at rest and during exerciseP Fitscha, I Virgolini, F Rauscha, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD)P Fitscha, B Tiso, T Krais, et al.
Lancet (London, England)|January 2, 1993
Enhanced in-vitro platelet aggregability during postprandial hyperlipidaemiaH Sinzinger, C Pirich, P Fitscha, et al.
Wiener Klinische Wochenschrift|November 4, 1988
[Defects in the prostaglandin system. VI. Acquired plasma factor defect]H Sinzinger, P Fitscha, F Rauscha, et al.
Lancet (London, England)|April 13, 1991
Calcium antagonists and hypercalcaemiaH Sinzinger, F Rauscha, P Fitscha, et al.
Progress in Clinical and Biological Research|January 1, 1987
Monitoring of in-vivo platelet deposition in patients with peripheral vascular disease after different doses of prostaglandin I2 (PGI2)E Strobl-Jäger, P Fitscha, J Kaliman, et al.
European Journal of Clinical Pharmacology|January 1, 1988
Haemodynamic effects of short-term treatment with bopindolol in essential hypertensionP Fitscha, W Meisner, G Brandstetter, et al.
British Journal of Clinical Pharmacology|March 1, 1992
Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in manH Sinzinger, F Rauscha, J O'Grady, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 15, 1999
Isradipine lowers human arterial low density lipoprotein retention in vivoH Kritz, H Sinzinger, P Fitscha, et al.
Blood Pressure. Supplement|January 1, 1994
Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wallC Pirich, P Fitscha, P Schmid, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
American Journal of Hypertension|February 1, 1991
Effects of isradipine on platelet function in hypertension at rest and during exerciseP Fitscha, I Virgolini, F Rauscha, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD)P Fitscha, B Tiso, T Krais, et al.
Lancet (London, England)|January 2, 1993
Enhanced in-vitro platelet aggregability during postprandial hyperlipidaemiaH Sinzinger, C Pirich, P Fitscha, et al.
Wiener Klinische Wochenschrift|November 4, 1988
[Defects in the prostaglandin system. VI. Acquired plasma factor defect]H Sinzinger, P Fitscha, F Rauscha, et al.
Lancet (London, England)|April 13, 1991
Calcium antagonists and hypercalcaemiaH Sinzinger, F Rauscha, P Fitscha, et al.
Progress in Clinical and Biological Research|January 1, 1987
Monitoring of in-vivo platelet deposition in patients with peripheral vascular disease after different doses of prostaglandin I2 (PGI2)E Strobl-Jäger, P Fitscha, J Kaliman, et al.
European Journal of Clinical Pharmacology|January 1, 1988
Haemodynamic effects of short-term treatment with bopindolol in essential hypertensionP Fitscha, W Meisner, G Brandstetter, et al.
British Journal of Clinical Pharmacology|March 1, 1992
Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in manH Sinzinger, F Rauscha, J O'Grady, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 15, 1999
Isradipine lowers human arterial low density lipoprotein retention in vivoH Kritz, H Sinzinger, P Fitscha, et al.
Blood Pressure. Supplement|January 1, 1994
Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wallC Pirich, P Fitscha, P Schmid, et al.
Pageof 13